Table 3.
OS and PFS in the 50 patients with locally advanced/metastatic pancreatic cancer, 18 patients receiving a full dose compared with the 32 patients receiving an attenuated dose
| Patients | Median OS (range) (months) |
Median PFS (range) (months) |
|---|---|---|
| All patients (n=50) | 10.07 (0.53-28.2) | 5.63 (0.4-21.93) |
| Receiving an attenuated doses (n=32) | 10.52 (0.53-28.2) | 5.70 (0.4-21.93) |
| Receiving a full doses (n=18) | 10.07 (1.0-24.3) | 6.13(0.77-21.5) |
| Metastatic (n=37) | 10.07 (0.53-28.2) | 5.63 (0.4-21.93) |
| Receiving an attenuated doses (n=23) | 10.52 (0.53-28.2) | 5.70 (0.4-21.93) |
| Receiving a full doses (n=14) | 10.90 (1.0-18.7) | 6.13 (0.77-14.43) |
| Locally advanced (n=13) | 11.47 (4.6-24.3) | 6.27 (1.3-21.5) |
| Receiving an attenuated doses (n=9) | 11.47 (4.6-15.6) | 5.98 (1.3-12.87) |
| Receiving a full doses (n=4) | 12.83 (15.9-24.3) | 7.10 (7.3-21.5) |
Abbreviations: OS, overall survival; PFS, progression-free survival.